Finasteride and MENT Interaction: Compatible | Peptide Database

Proviron is one of the most reliable compounds for improving sexual desire and drive. Its DHT activity directly stimulates libido pathways, while its SHBG-binding effect increases free testosterone availability. Effects are often noticeable within the first week of use. By increasing free testosterone and DHT activity, Proviron can improve erectile firmness and frequency. Particularly effective in men whose erectile issues are related to low free testosterone or elevated SHBG. At doses of 25-50 mg/day, Proviron has been used clinically to improve sperm count and motility in oligospermic men. At these low doses, HPT axis suppression is minimal. Higher doses may suppress spermatogenesis. Proviron is widely reported to produce a noticeable improvement in mood, confidence, and overall psychological well-being. This is attributed to increased free testosterone and direct androgenic activity in the central nervous system. Many users describe a calm, confident, and motivated mindset. In men with documented androgen deficiency, Proviron has been used to alleviate depressive symptoms, fatigue, and loss of motivation. Not a replacement for standard psychiatric treatment but can complement hormonal optimization. Proviron reduces water retention and gives a visibly harder, more defined appearance. It does not significantly build muscle mass on its own due to rapid inactivation in muscle tissue, but it enhances the aesthetic quality of existing musculature. By binding SHBG and freeing bound testosterone, Proviron effectively increases the anabolic signal from a given testosterone dose. This makes it a potent adjunct to any testosterone-based protocol for improving body composition outcomes. Proviron has one of the highest binding affinities for SHBG of any androgen. This displaces testosterone from SHBG, increasing free testosterone without increasing total testosterone dose. Particularly useful in men with elevated SHBG who present with low free testosterone despite adequate total testosterone levels. Proviron provides a mild anti-estrogenic effect through aromatase competition, which can reduce or eliminate the need for a dedicated aromatase inhibitor on moderate testosterone doses. It is not a replacement for an AI in heavily aromatizing protocols but can meaningfully reduce estrogen-related side effects in standard TRT.

First-line treatment for elevated LDL cholesterol and mixed dyslipidemia. Rosuvastatin 10-20 mg achieves LDL reductions of 45-55%, outperforming equivalent doses of other statins. Particularly appropriate when aggressive LDL lowering is required or when patients have not reached lipid targets on less potent statins. Widely used off-label to manage lipid disturbances caused by anabolic steroid cycles, especially oral AAS (oxandrolone, stanozolol, methandrostenolone) that severely impact lipid profiles. Typical on-cycle doses of 5-10 mg daily can meaningfully reduce LDL elevation, though HDL suppression caused by androgens is only partially mitigated. Most effective when started before or at the beginning of a cycle rather than reactively. Proven to reduce major cardiovascular events including myocardial infarction, stroke, and cardiovascular death. The JUPITER trial showed a 44% reduction in major cardiovascular events in apparently healthy individuals with elevated hsCRP. Particularly relevant for long-term AAS users who accumulate cardiovascular risk over time. Indicated for cardiovascular risk reduction in individuals without established cardiovascular disease but with risk factors such as dyslipidemia, family history, or elevated inflammatory markers. The JUPITER trial established benefit even in patients with LDL below 130 mg/dL if hsCRP was elevated above 2 mg/L. The METEOR trial demonstrated that rosuvastatin 40 mg significantly slowed progression of carotid intima-media thickness compared to placebo in low-risk patients with subclinical atherosclerosis. Suggests benefit in slowing vascular damage that may accumulate in chronic AAS users.